The FDA approved Semaglutide in 2014 for Type 2 diabetes to lower blood sugar and maintain blood sugar levels. Type 2 diabetes is a condition when the body does not use insulin properly and cannot manage the amount of sugar in the blood.
During clinical trials, it was discovered that Semaglutide had other benefits, including improved cardiovascular risk, decreased inflammation, decreased appetite, and weight loss. As a result, in 2019, Semaglutide was FDA approved for use in patients with a BMI of 30 or greater, or a BMI of 27 and greater with at least one comorbidity, for weight management.
Semaglutide is a glucagon-like peptide-1 receptor agonist. It imitates the action of the incretin GL-1 by increasing the production of insulin or a hormone that lowers blood sugar levels. Semaglutide for weight loss works by suppressing your appetite, and the peptide semaglutide replicates in the areas of the brain that regulate appetite and food intake. In addition to using Semaglutide, an exercise program and reduced caloric intake will aid in weight loss goals and long-term management.
Fillers are used to
Brand names are Wegovy, Ozempic, and Rybelsus. Wegovy and Ozempic are injections, and Rybelsus is a tablet.
Semaglutide for weight loss is a subcutaneous injection given once a week at home.
You may experience nausea, vomiting, diarrhea, abdominal pain, and constipation. If you have heart problems, it can cause damage. Other less common side effects include elevated heart rate, allergic reactions, low blood sugar, pancreatitis, thyroid tumors, and kidney problems.
Dosages are based on health conditions and your response to the treatments. Start at a low dose and gradually increase your intake. Follow your provider’s instructions. Semaglutide for weight loss is typically used for 3- 6 months.